BiomX Inc. (NYSEAMERICAN:PHGE) Short Interest Down 50.6% in February

BiomX Inc. (NYSEAMERICAN:PHGE) was the recipient of a significant drop in short interest in February. As of February 13th, there was short interest totaling 133,660 shares, a drop of 50.6% from the January 29th total of 270,744 shares. Currently, 10.7% of the shares of the stock are short sold. Based on an average trading volume of 147,073 shares, the days-to-cover ratio is presently 0.9 days. Based on an average trading volume of 147,073 shares, the days-to-cover ratio is presently 0.9 days. Currently, 10.7% of the shares of the stock are short sold.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in BiomX stock. Citadel Advisors LLC purchased a new stake in shares of BiomX Inc. (NYSEAMERICAN:PHGE) during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 161,781 shares of the company’s stock, valued at approximately $85,000. Citadel Advisors LLC owned approximately 0.61% of BiomX as of its most recent SEC filing. 40.57% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Separately, HC Wainwright reissued a “buy” rating on shares of BiomX in a research note on Tuesday, November 25th. One investment analyst has rated the stock with a Buy rating, Based on data from MarketBeat, BiomX currently has a consensus rating of “Buy” and a consensus target price of $26.00.

BiomX Stock Performance

Shares of BiomX stock traded down $0.20 during midday trading on Friday, reaching $4.37. 31,756 shares of the company’s stock traded hands, compared to its average volume of 94,031. The stock has a 50 day moving average of $3.90 and a 200-day moving average of $6.72. BiomX has a 12 month low of $1.50 and a 12 month high of $14.71. The company has a market cap of $6.95 million, a PE ratio of -0.17 and a beta of 1.68.

BiomX Company Profile

BiomX Inc is a clinical-stage biotechnology company that specializes in developing precision bacteriophage therapies to target pathogenic bacteria in the human microbiome. By harnessing the natural ability of bacteriophages to selectively infect and lyse harmful bacterial strains, BiomX aims to restore microbial balance without disrupting beneficial commensal organisms. The company’s platform integrates phage discovery, formulation and genetic engineering to create tailored phage cocktails for a range of microbiome-associated diseases.

The company’s pipeline includes lead clinical candidates for gastrointestinal disorders such as pouchitis and ulcerative colitis, as well as programs addressing dermatological indications including acne and atopic dermatitis.